Treatment for Smoldering (Pre-Cancerous) Myeloma
Study name: Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM)
Description: Researchers at the WL Nugent Cancer Center are conducting a Phase III clinical trial for treating smoldering myeloma to determine if patient outcomes improve when taking an immunotherapy medication (called daratumumab) combined with standard chemotherapy treatment. Immunotherapy medications use your body’s immune system to fight cancer.
- Group 1 (investigational treatment): Receive immunotherapy medication (daratumumab) combined with standard chemotherapy medications (lenalidomide and dexamethasone).
- Group 2 (current standard treatment): Receive standard chemotherapy medications (lenalidomide and dexamethasone) alone.
The goal of this study is to identify if the combination of immunotherapy and chemotherapy is effective in slowing the progression of smoldering multiple myeloma.
Who can participate?
This study is open to men and women age 18 and over who:
- Have been diagnosed with asymptomatic (smoldering) multiple myeloma
- Had no prior myeloma treatment (including radiation therapy).
What to expect
-
You will meet with your doctor to discuss what is involved in the study and the possible benefits and risks. If you and your doctor agree this clinical trial is right for you, you will be asked to sign a consent form.
-
This is a randomized study, where you will be assigned by chance to one of the treatment groups listed above.
-
You will periodically complete questionnaires about your condition, side-effects from treatment, etc.
-
Blood samples may be collected before, during, and after treatment for study analysis.
Please talk with your doctor about whether this clinical trial is right for you.